Citizens Initiates Coverage#
Citizens has begun coverage on Celcuity Inc (NASDAQ:CELC) with a Market Outperform rating. This rating suggests that they expect the stock to perform better than the overall market. Citizens has set a price target of $150.00, aligning with a generally optimistic view among analysts, whose price targets for Celcuity range from $94 to $155.
Company Overview#
Celcuity is a clinical-stage biotechnology company with a market capitalization of $5.8 billion. It specializes in developing targeted therapies for cancer treatment. Over the past year, Celcuity's stock has seen remarkable growth, increasing by over 1,020%. Currently, it trades at approximately $121.03, close to its 52-week high of $128.28. However, some analysts suggest that the stock may be overvalued at this price level.
Analyst Insights#
Silvan Turkcan, an analyst at Citizens, highlighted that Celcuity's gedatolisib regimen could be a promising treatment option as it targets multiple cancer pathways simultaneously. The firm is optimistic about upcoming data from the VICTORIA-1 study, which focuses on patients with specific genetic mutations. They also anticipate a potential approval for another treatment in July.
Recent Financial Performance#
In its latest earnings report for the fourth quarter of 2025, Celcuity posted an earnings per share (EPS) of -$0.73, which was better than the expected -$1.05, marking a positive surprise of 30.48%. Following this report, Craig-Hallum raised its price target for Celcuity to $141, while Stifel increased its target to $125. Both firms maintain a Buy rating, reflecting confidence in Celcuity's pipeline and future prospects. Meanwhile, H.C. Wainwright has a Neutral rating with a price target of $94, indicating a more cautious outlook on the company's current valuation.